VASCULAR EMBOLIZATION MARKET ANALYSIS

Embolization is a minimally invasive treatment (an alternative to open surgery) that blocks one or more blood vessels or abnormal vascular channels. Embolization procedures allow blockage of blood vessels without invasive surgery. Embolization can be used to stop arterial bleeding, and can also be used to block blood vessels for other reasons, such as to treat tumors, re-direct flow, or shrink vascular malformations, among others. Embolization is a very common and effective procedure in interventional radiology. Vascular embolization agents are used to stop flow in blood vessel or vascular area by the means of mechanical occlusion. High success rate, rare use of general anesthetics, faster recovery time, minimal risk of infection, and no scarring are some features of vascular embolization agents.

Market Statistics:

The global vascular embolization market is estimated to be valued at USD 1,932.9 Mn in 2024 and is expected to exhibit a CAGR of 9.5% during the forecast period (2024-2031). 

North America held dominant position in the global vascular embolization market in 2020, accounting for 41.2% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Vascular Embolization Market Value (USD MN), by Region, 2024

To learn more about this report, request a free sample copy

Market Drivers:

• Increasing prevalence of vascular diseases across the globe is expected to propel the growth of the global vascular embolization market during the forecast period. Vascular disease is any condition that affects the network of blood vessels. They are common and can be serious. For instance, according to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. This represents 35% of global deaths.
• Advancements in embolization products and procedures is expected to augment the growth of the global vascular embolization market over the forecast period. For instance, in July 2021, Terumo Medical Corporation announced the launch of its AZUR Vascular Plug, the first and only plug compatible with a micro-catheter to occlude arteries up to 8mm in diameter. The new addition to Terumo's robust embolization portfolio is indicated for use to reduce or block the rate of blood flow in arteries of the peripheral vasculature.

Figure 2. Global Vascular Embolization Market Share, By Embolization Technique, 2024 

To learn more about this report, request a free sample copy

Recent Developments

In January 2023, Fluidx Medical Technology, Inc., a privately-held medical device company, announced the success of the IMPASS Embolic Device in in-vivo studies of middle meningeal artery (MMA) embolizations, which can be used to treat chronic subdural hematomas (CSDH) on the brain's surface.

In November 2022, Varian, a Siemens Healthineers company, announced that the first trial participant had been treated as part of GENESIS II (Genicular Artery Embolization in Patients with Knee Osteoarthritis), a study of embozene microspheres for genicular artery embolization (GAE) as a treatment for mild to moderate knee osteoarthritis. GENESIS II is GAE's largest randomized clinical trial to evaluate pain alleviation for this chronic illness.

In August 2022, Boston Scientific Corporation, a medical device company, announced the acquisition of Obsidio, Inc., a privately-held company that created Gel Embolic Material (GEM) technology for embolizing blood vessels in the peripheral vasculature. GEM technology, approved by the U.S. Food and Drug Administration (FDA), is a semi-solid, patented material packaged in a ready-to-use form, decreasing the preparation time required for various embolization treatments.

In April 2021, Medtronic plc, a global pioneer in medical technology, gained U.S. FDA approval for its Pipeline Flex Embolization Device with Shield Technology. Medtronic plc developed Shield Technology, a proprietary breakthrough in biomaterial science, to advance flow diversion therapy by introducing the first surface-modified implant device with reduced material thrombogenicity, or the ability of the surface treatment material to form clots. NYU Langone Health in New York City completed the U.S’s first patient procedure with the novel technology.

Market Restraints:

• Complications associated with embolization procedures is expected to hinder growth of the global vascular embolization market. There is always a chance that an embolic agent can lodge in the wrong place and deprive normal tissue of its oxygen supply. There is a risk of infection after embolization, even if an antibiotic has been given. In patients with liver cancer that are treated using embolism develops, fever, pain in the right hypochondrium (region of abdomen), and a rise in transaminases as complications.
• High cost of embolization procedures is expected to hamper the growth of the global vascular embolization market. Although the procedure has numerous benefits, it is expensive, especially for the needful patients in developed/developing countries. The prevalence of vascular diseases is increasing globally. However, due to the higher costs of procedures, access to these facilities is prohibited in developing and underdeveloped countries.

Market Opportunities:

• Increasing preference for minimally invasive procedures is expected to provide significant growth opportunities for players in the market. For instance, according to the American College of Cardiology, in 2020, around 1.2 million angioplasties were performed in a year in the United States. Moreover, the high accessibility and affordability of hospitals, compared to the specialty clinics, are expected to attract a large patient population.
• Increase in demand for novel treatments is expected to offer lucrative growth opportunities for players in the market. For instance, in December 2020, Terumo Corporation launched WEB Embolization System, an intrasaccular aneurysm treatment device, in Japan to provide novel treatment options for brain aneurysm cases that were difficult to treat with currently approved methods. It is a first-of-its-kind intrasaccular flow disruptor device available in Japan.

Market Trends/Key Takeaways:

1. Surge in usage of clot agents is expected to drive growth of the global vascular embolization market. For instance, in October 2020, Cerenovus, part of Johnson & Johnson Medical Devices Companies, announced the European launch of CERENOVUS NIMBUS, designed to remove tough clots for successful revascularization in patients with acute ischemic stroke caused by a large vessel occlusion. Cerenovus Nimbus is designed to remove tough clot.
2. Rise in cases of automobile accidents across the globe is expected to augment growth of the global vascular embolization market. For instance, embolization provides expedited/minimally invasive control of bleeding with less disruption of normal tissues than surgery, and plays vital role in the non-operative management of many traumatic injuries, resulting in a decreased need for blood transfusion and improved survival. According to WHO, road traffic injuries are the leading cause of death, around 1.3 million people die each year as a result of road accidents.

Competitive Landscape:

1. Medtronic PLC
2. Cook Medical
3. Stryker Corporation
4. Boston Scientific Corporation
5. Abbott Laboratories
6. Johnson and Johnson (Cerenovus)
7. Merit Medical Systems Inc.
8. Penumbra Inc.
9. Terumo Corp
10. Shape Memory Medical Inc.